Sernova Biotherapeutics Inc.SVA.TO
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · sernova.com
Sernova Biotherapeutics Inc. is a clinical-stage Canadian regenerative medicine company developing its Cell Pouch bio-hybrid organ system to treat chronic diseases such as Type 1 diabetes. The Cell Pouch creates a vascularized environment enabling transplanted therapeutic cells to survive and function long-term. The company is headquartered in London, Ontario.
Key ratios
ROA
-377.0%TTM
2025
-226.5%2024
-133.6%2023
-67.9%
ROE
-726.3%TTM
2023
-129.7%
Recent news
Seraxis and Sernova Announce Appointment of Former FDA Medical Officer Dr. Patricia Beaston as Chief Medical Officer of Seraxis and Post-Merger BetaNova Biotherapeutics
Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial
Sernova Biotherapeutics to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference
Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc.
Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy
Track SVA.TO in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer